Our data showed varied distribution of MSC population (defined by co-expression of CD73, CD90 and CD105 and negative for all hematopoietic markers, such as lineage markers as well as CD34 progenitors) in differently treated MM patients (REL and REF MM patients) compared to untreated MM patient samples in premalignant (SMM) or newly diagnosed (ND) active MM stages. This evidence concerns the gene NT5E and Miyoshi myopathy.